0000000001088015

AUTHOR

Gianluca Campo

showing 5 related works from this author

Grip strength predicts cardiac adverse events in patients with cardiac disorders: an individual patient pooled meta-analysis.

2019

ObjectiveGrip strength is a well-characterised measure of weakness and of poor muscle performance, but there is a lack of consensus on its prognostic implications in terms of cardiac adverse events in patients with cardiac disorders.MethodsArticles were searched in PubMed, Cochrane Library, BioMed Central and EMBASE. The main inclusion criteria were patients with cardiac disorders (ischaemic heart disease, heart failure (HF), cardiomyopathies, valvulopathies, arrhythmias); evaluation of grip strength by handheld dynamometer; and relation between grip strength and outcomes. The endpoints of the study were cardiac death, all-cause mortality, hospital admission for HF, cerebrovascular accident…

medicine.medical_specialtyWeaknessMultivariate analysisHeart diseaseHeart Diseasesheart failure030204 cardiovascular system & hematologyCochrane LibraryHeart diseaseGlobal HealthNO03 medical and health sciencesGrip strength0302 clinical medicinePatient AdmissionInternal medicineCause of DeathHeart disease; heart failure; meta-analysis; Cardiology and Cardiovascular MedicinemedicineHumans030212 general & internal medicineMyocardial infarctionHand Strengthbusiness.industrymedicine.diseasePrognosishumanitiesSurvival Ratemeta-analysisCardiovascular System & HematologyMeta-analysisHeart failureCardiologymedicine.symptombusinessCardiology and Cardiovascular Medicine
researchProduct

The assessment of scales of frailty and physical performance improves prediction of major adverse cardiac events in older adults with acute coronary …

2019

Abstract Background The number of older adults admitted to hospital for acute coronary syndrome (ACS) has increased worldwide. The aim of this study was to determine which scale of frailty or physical performance provides incremental improvements in risk stratification of older adults after ACS. Methods A prospective cohort of 402 older (≥70 years) ACS patients were enrolled. Data about baseline characteristics, Global Registry of Acute Coronary Events (GRACE), and Thrombolysis in Myocardial Infarction (TIMI) risk scores were collected. Before hospital discharge, seven scales of frailty and physical performance were measured. The 1-year occurrence of adverse events (cardiac death, reinfarct…

MaleAgingAcute coronary syndromemedicine.medical_specialtymedicine.medical_treatmentAcute coronary syndrome; ST-segment elevation myocardial infarction; frailty; short physical performance batteryshort physical performance batteryfrailty030204 cardiovascular system & hematologyRisk AssessmentStatistics NonparametricNO03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansProspective Studies030212 general & internal medicineMyocardial infarctionAdverse effectProspective cohort studyGeriatric AssessmentAgedbusiness.industryConfoundingThrombolysismedicine.diseaseClinical trialST-segment elevation myocardial infarctionPhysical FitnessExercise TestCardiologyFemaleAcute coronary syndromeGeriatrics and GerontologybusinessTIMI
researchProduct

Nutritional status and all-cause mortality in older adults with acute coronary syndrome.

2020

Background & aims The present analysis investigated the prevalence and the prognostic implication of nutritional status in older adults hospitalized for acute coronary syndrome (ACS). Methods The analysis is based on older ACS patients included in the FRASER and LONGEVO SCA studies. The Global Risk of Acute Coronary Events (GRACE) risk score was computed in all patients. Nutritional status was assessed with the Mini Nutritional Assessment-Short Form (MNA-SF, normal for values between 12 and 14, at risk of malnutrition for values between 8 and 11, and malnutrition for values ≤ 7). Physical performance was assessed with the Short Physical Performance Battery (SPPB). Primary outcome was all-ca…

0301 basic medicineAcute coronary syndromemedicine.medical_specialtyAncianoEnfermedad cardiovascularShort Physical Performance BatteryNutritional Status030209 endocrinology & metabolismCritical Care and Intensive Care MedicineNO03 medical and health sciences0302 clinical medicineElderlyInternal medicineCause of DeathEnfermos cardíacosmedicineClinical endpointHumansAcute Coronary SyndromeMortalityNutritionAgedAcute coronary syndrome; Elderly; Mortality; NutritionAged 80 and over030109 nutrition & dieteticsNutrition and DieteticsFramingham Risk Scorebusiness.industryMortality rateMalnutritionNutritional statusmedicine.diseaseMalnutritionNutriciónAcute coronary syndromebusinessAncianosAll cause mortalityClinical nutrition (Edinburgh, Scotland)
researchProduct

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian …

2022

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). Methods: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition…

MaleTicagrelorAspirinMyocardial InfarctionAnticoagulantsHemorrhageFactor XIaPercutaneous Coronary InterventionTreatment OutcomeDouble-Blind MethodPhysiology (medical)HumansFemale03.02. Klinikai orvostanAcute Coronary SyndromeCardiology and Cardiovascular MedicinePrasugrel HydrochloridePlatelet Aggregation InhibitorsAgedCirculation
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct